PALI — Palisade Bio, Inc.

Is PALI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Palisade Bio, Inc. (PALI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.03. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Palisade Bio, Inc. (PALI) is a small-cap, pipeline-dependent biotech with valuation tied to clinical and partnership catalysts. Public disclosure gaps and a challenging funding backdrop elevate dilution risk; sector flows favoring large-cap pharma limit near-term investor demand. Short-term upside is possible if positive data or a deal emerges, but cash runway, trial execution, and competitive dynamics present material downside scenarios.

Key factors

  • Biotech with pipeline- and data-driven valuation: near-term upside depends heavily on clinical readouts or partnership activity.
  • Limited public financial disclosure and EDGAR analysis available, creating uncertainty about cash runway and financing needs.
  • Market environment currently favors large-cap pharma and defensive healthcare names, reducing investor appetite for micro-cap biotech risk.
  • Sector signals around convertible-debt and dilution in mid/small-cap biotech increase probability of future equity issuance.
  • Risk-on sessions can temporarily lift speculative names, supporting short-term price resilience if headlines or news catalysts appear.
  • Low liquidity and small market capitalization amplify price volatility around news and trading flows.

Risks

  • Insufficient cash runway leading to dilutive financing or unfavorable financing terms.
  • Clinical trial failures, regulatory setbacks, or delayed readouts that materially reduce expected upside.
  • Competitive pressure from larger pharma or alternative therapies eroding addressable market for pipeline assets.
  • High stock volatility and low trading volume causing sharp price moves unrelated to fundamentals.
  • Sector rotation into large-cap defensive healthcare could reduce interest and secondary-market support.
  • Lack of recent filings and limited social/research coverage creating information asymmetry and investor uncertainty.
  • Macroeconomic or funding environment shifts that increase cost of capital for small-cap biotechs.

See today's live rating, score and targets

Members see the live hourly rating for PALI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.